In the last trading session, 4.62 million shares of the Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) were traded, and its beta was 0.01. Most recently the company’s share price was $2.84, and it changed around -$0.18 or -5.96% from the last close, which brings the market valuation of the company to $717.18M. MRVI currently trades at a discount to its 52-week high of $11.56, offering almost -307.04% off that amount. The share price’s 52-week low was $2.93, which indicates that the current value has fallen by an impressive -3.17% since then.
Maravai LifeSciences Holdings Inc stock received a consensus recommendation rating of Buy, based on a mean score of 2.20. If we narrow it down even further, the data shows that 0 out of 16 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 7 recommended MRVI as a Hold, whereas 7 deemed it a Buy, and 1 rated it as Underweight. Maravai LifeSciences Holdings Inc is expected to report earnings per share of -0.04 for the current quarter.
Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) trade information
Instantly MRVI has showed a red trend with a performance of -5.96% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 3.33 on recent trading dayincreased the stock’s daily price by 14.71%. The company’s shares are currently down -47.89% year-to-date, but still down -9.55% over the last five days. On the other hand, Maravai LifeSciences Holdings Inc (NASDAQ:MRVI) is -42.39% down in the 30-day period.
The consensus price target as assigned by Wall Street analysts is $22, which translates to bulls needing to increase their stock price by 87.09% from its current value. Analyst projections state that MRVI is forecast to be at a low of $10 and a high of $25.
Maravai LifeSciences Holdings Inc (MRVI) estimates and forecasts
The year-over-year growth rate is expected to be -9.83%, down from the previous year.
Consensus estimates provided by 12 financial analysts predict the company will bring in an average of 57.79M in revenue for the current quarter. 12 analysts expect Maravai LifeSciences Holdings Inc to make 63.15M in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 74.14M and 64.18M respectively. Analysts predict that the company’s current quarter sales will drop, forecast at -22.06%. Forecasts for the next quarter put sales growth at -1.61%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -37.53%.
MRVI Dividends
Maravai LifeSciences Holdings Inc’s next quarterly earnings report is expected to be released in April.
12 WEST CAPITAL MANAGEMENT LP, with 9.7254% or 13.21 million shares worth $94.59 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Vanguard Total Stock Market Index Fund and Vanguard Small-Cap Index Fund were the top two Mutual Funds as of Sep 30, 2024 . The former held 3.94 shares worth $11.18 million, making up 2.78% of all outstanding shares. On the other hand, Vanguard Small-Cap Index Fund held roughly 3.02 shares worth around $8.57 million, which represents about 2.13% of the total shares outstanding.
